Aryl carbonyl derivatives as therapeutic agents
View Patent ↗This invention relates to aryl carbonyl derivatives which are activators of glucokinase which may be useful for the management, treatment, control, or adjunct treatment of diseases, where increasing glucokinase activity is beneficial.
1. A compound of Formula (Ib)
wherein
R 24 is selected from the group consisting of F, Cl, Br, and —CH 3 ;
L 1 is selected from the group consisting of -D-alkylene-E- and —O—; D is —O—; E is a direct bond;
G 1 is selected from the group consisting of methyl, ethyl, propyl, butyl, isopropyl, isobutyl, sec-butyl, tert-butyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, tetrahydrofuranyl, tetrahydropyranyl, pyrrolidyl, piperidyl, hexahydroazepinyl, thiolanyl, tetrahydrothiopyranyl, and thiepanyl;
L 2 is —N—(R 20 )—; R 20 is H;
L 3 is —C(O)—;
R 1 is hydrogen;
G 2 is
R 43 is —C 1-6 -alkylene-C(O)OR 54 ;
R 54 is selected from the group consisting of hydrogen, methyl, ethyl, propyl, butyl, isopropyl, isobutyl, sec-butyl, tert-butyl, 3-pentyl, 2-pentyl, and 3-methyl-butyl;
or a pharmaceutically acceptable salt or solvate thereof.
2. The compound, pharmaceutically acceptable salt or solvate thereof of claim 1 , wherein G 1 is isobutyl.
3. The compound, pharmaceutically acceptable salt or solvate thereof of claim 1 , wherein R 24 is methyl.
4. The compound, pharmaceutically acceptable salt or solvate thereof of claim 2 , wherein R 24 is methyl.
5. The compound, pharmaceutically acceptable salt or solvate thereof of claim 1 , wherein R 54 is hydrogen.
6. The compound, pharmaceutically acceptable salt or solvate thereof of claim 2 , wherein R 54 is hydrogen.
7. The compound, pharmaceutically acceptable salt or solvate thereof of claim 3 , wherein R 54 is hydrogen.
8. The compound, pharmaceutically acceptable salt or solvate thereof of claim 4 , wherein R 54 is hydrogen.
9. The compound, pharmaceutically acceptable salt or solvate thereof of claim 1 , wherein R 43 is —CH 2 —C(O)OR 54 .
10. The compound of claim 1 , wherein the compound is selected from the group consisting of:
{2-[3-(4-Methyl-2-[2-methypropoxy]phenyl)-ureido]-thiazol-4-yl}-acetic acid ethyl ester;
{2-[3-(4-methyl-2-[2-methylpropoxy]phenyl)-ureido]-thiazol-4-yl}-acetic acid;
{2-[3-(2-Cyclopropylmethoxy-4-methyl-phenyl)-ureido]-thiazol-4-yl}-acetic acid ethyl ester;
{2-[3-(2-Cyclopropylmethoxy-4-methyl-phenyl)-ureido]-thiazol-4-yl}-acetic acid;
{2-[3-(2-Cyclopentyloxy-4-methyl-phenyl)-ureido]-thiazol-4-yl}-acetic acid ethyl ester; and
{2-[3-(2-Cyclopentyloxy-4-methyl-phenyl)-ureido]-thiazol-4-yl}-acetic acid,
or a pharmaceutically acceptable salt or solvate thereof.
11. The compound {2-[3-(4-methyl-2-[2-methylpropoxy]phenyl)-ureido]-thiazol-4-yl}-acetic acid or a pharmaceutically acceptable salt or solvate thereof.
12. A pharmaceutical composition comprising the compound of Formula (Ib)
wherein
R 24 is selected from the group consisting of F, Cl, Br, and —CH 3 ;
L 1 is selected from the group consisting of -D-alkylene-E- and —O—; D is —O—; E is a direct bond;
G 1 is selected from the group consisting of methyl, ethyl, propyl, butyl, isopropyl, isobutyl, sec-butyl, tert-butyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, tetrahydrofuranyl, tetrahydropyranyl, pyrrolidyl, piperidyl, hexahydroazepinyl, thiolanyl, tetrahydrothiopyranyl, and thiepanyl;
L 2 is —N—(R 20 )—; R 20 is H;
L 3 is —C(O)—;
R 1 is hydrogen;
G 2 is
R 43 is —C 1-6 -alkylene-C(O)OR 54 ;
R 54 is selected from the group consisting of hydrogen, methyl, ethyl, propyl, butyl, isopropyl, isobutyl, sec-butyl, tert-butyl, 3-pentyl, 2-pentyl, and 3-methyl-butyl;
or a pharmaceutically acceptable salt or solvate thereof;
and a pharmaceutically acceptable carrier, diluent, excipient, or mixture thereof.
13. The pharmaceutical composition of claim 12 , wherein G 1 is isobutyl.
14. The pharmaceutical composition of claim 12 , wherein R 24 is methyl.
15. The pharmaceutical composition of claim 13 , wherein R 24 is methyl.
16. The pharmaceutical composition of claim 12 , wherein R 54 is hydrogen.
17. The pharmaceutical composition of claim 13 , wherein R 54 is hydrogen.
18. The pharmaceutical composition of claim 14 , wherein R 54 is hydrogen.
19. The pharmaceutical composition of claim 15 , wherein R 54 is hydrogen.
20. The pharmaceutical composition of claim 12 , wherein R 43 is —CH 2 —C(O)OR 54 .
21. The pharmaceutical composition of claim 12 , wherein the compound is selected from the group consisting of {2-[3-(4-Methyl-2-[2-methypropoxy]phenyl)-ureido]-thiazol-4-yl}-acetic acid ethyl ester;
{2-[3-(4-methyl-2-[2-methylpropoxy]phenyl)-ureido]-thiazol-4-yl}-acetic acid;
{2-[3-(2-Cyclopropylmethoxy-4-methyl-phenyl)-ureido]-thiazol-4-yl}-acetic acid ethyl ester;
{2-[3-(2-Cyclopropylmethoxy-4-methyl-phenyl)-ureido]-thiazol-4-yl}-acetic acid;
{2-[3-(2-Cyclopentyloxy-4-methyl-phenyl)-ureido]-thiazol-4-yl}-acetic acid ethyl ester; and
{2-[3-(2-Cyclopentyloxy-4-methyl-phenyl)-ureido]-thiazol-4-yl}-acetic acid,
or a pharmaceutically acceptable salt or solvate thereof.
22. A pharmaceutical composition comprising the compound {2-[3-(4-methyl-2-[-2-methylpropoxy]phenyl)-ureido]-thiazol-4-yl}-acetic acid or a pharmaceutically acceptable salt or solvate thereof; and a pharmaceutically acceptable carrier, diluent, excipient, or mixture thereof.